---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-003430"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:45:00.168556+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioCryst shareholders approve 7M-share increase to Stock Incentive Plan

## Summary
- Stockholders approved amendment increasing authorized shares by 7,000,000 to 70,090,000 total under the plan.
- Directors re-elected: Nancy J. Hutson, Vincent J. Milano, A. Machelle Sanders; broker non-votes 26,962,524.
- Ernst & Young ratified as FY 2024 auditor (167,496,029 for); advisory exec-comp resolution passed (138,402,008 for).
- Incentive Plan Proposal passed with 101,846,368 for, 43,055,807 against; plan now includes 12-month minimum vesting.

## SEC filing metadata
- accession: 0001171843-24-003430
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184324003430/0001171843-24-003430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184324003430/f8k_061324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-003430
- JSON: https://secwatch.observer/filing/0001171843-24-003430.json
- Plain text: https://secwatch.observer/filing/0001171843-24-003430.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.